Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-10
Gold Daniel Allen Files Roivant Sciences Ltd. (ROIV) Form 4 - September 10, 2026
Gold Daniel Allen sold 5.1K ROIV shares worth $210.1K in this Form 4 filing, reported to the SEC on 2026-09-10.
- Insider
- Gold Daniel Allen
- Issuer
- Roivant Sciences Ltd. ROIV · NASDAQ
- Filed
- Period
- 2026-09-10
- Accession
- 0001140361-26-036535
- Source
- Official filing on sec.gov ↗
Transactions (1)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Gold Daniel Allen | 2026-09-10 | Sell | 5.1K | $40.94 | $210.1K | Direct |
| Net change | −5.1K | −$210.1K | ||||
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.
Track ROIV insider activity
Get alerted when Roivant Sciences Ltd. executives buy or sell their shares.